Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha, Sun Young Rha, Do-Youn Oh et al. · The Lancet Oncology · 2023
Cited by 689 works. doi:10.1016/s1470-2045(23)00515-6
Authors
- Sun Young Rha
- Patricio Eduardo Yanez
- Yuxian Bai
- Fernando Rivera
- Gustavo Vasconcelos Alves
- Marcelo Garrido S
- Kai‐Keen Shiu
- Felipe Melo Cruz
- Suxia Luo
References
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
- THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Comparative analysis of two rates
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- A graphical approach to sequentially rejective multiple test procedures
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer